Cost-effectiveness modelling of low-dose aspirin for the primary prevention of cardiovascular disease.

被引：0
|
作者：
Liew, D [1 ]
Vos, T [1 ]
Bertram, M [1 ]
Lim, S [1 ]
McNeil, JJ [1 ]
机构：
[1] Monash Univ, Melbourne, Vic 3004, Australia
来源：
CIRCULATION | 2004年 / 109卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P49
引用
收藏
页码：E90 / E90
页数：1
相关论文
共 50 条
  • [41] A COST-EFFECTIVENESS ANA LYSIS OF ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES AND COLORECTAL CANCER
    Soon, S.
    Chia, W. J.
    Redekop, K.
    Wee, H. L.
    VALUE IN HEALTH, 2015, 18 (07) : A462 - A462
  • [42] Low-dose aspirin and cardiovascular disease in women
    不详
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2005, 95 (05): : 327 - 327
  • [43] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [44] Smoking cessation for primary prevention of cardiovascular disease: A cost-effectiveness analysis
    Kinderen, AJD
    Oh, F
    De Laet, C
    VALUE IN HEALTH, 2004, 7 (06) : 692 - 693
  • [45] COST-EFFECTIVENESS OF EICOSAPENTAENOIC ACID (EPA) ON PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
    Kodera, S.
    Kiyosue, A.
    Ando, J.
    Komuro, I
    VALUE IN HEALTH, 2017, 20 (09) : A614 - A614
  • [46] The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
    van Gils, Paul F.
    Over, Eelco A. B.
    Hamberg-van Reenen, Heleen H.
    de Wit, G. Ardine
    van den Berg, Matthijs
    Schuit, Albertine J.
    Engelfriet, Peter M.
    BMJ OPEN, 2011, 1 (02):
  • [47] Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
    Djatche L.M.
    Varga S.
    Lieberthal R.D.
    PharmacoEconomics - Open, 2018, 2 (4) : 371 - 380
  • [48] THE POLYPILL IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: COST-EFFECTIVENESS IN THE DUTCH POPULATION
    Van Gils, P. F.
    Hamberg-Van Reenen, H. H.
    Over, E.
    de Wit, G. A.
    van den Berg, M.
    Schuit, A. J.
    Engelfriet, P. M.
    VALUE IN HEALTH, 2011, 14 (07) : A381 - A381
  • [49] Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk
    Greving, Jacoba P.
    Buskens, Erik
    Koffijberg, Hendrik
    Algra, Ale
    CIRCULATION, 2008, 117 (22) : 2875 - 2883
  • [50] A Practical Approach to Low-Dose Aspirin for Primary Prevention
    Chiang, Kim F.
    Shah, Shreya J.
    Stafford, Randall S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (04): : 301 - 302
12345